Article -> Article Details
Title | Human Immunodeficiency Virus (HIV) Drugs Market - Regional Analysis by 2023 |
---|---|
Category | Fitness Health --> Men's Health |
Meta Keywords | Human Immunodeficiency Virus (HIV) Drugs Market |
Owner | vinit |
Description | |
Market Highlights According to MRFR analysis, HIV
Drugs Market is expected to register a CAGR of 5% during
the forecast period of 2019 to 2025 and was valued at USD
24 million in 2018. HIV drugs aim to control the growth of the human
immunodeficiency virus (HIV), improve the patient’s overall immune system, and
reduce/stop the symptoms. The drugs used to treat HIV infection are
antiretrovirals, which help reduce the viral load and fight the infection. The growth of the global HIV drug market is driven by the
increasing prevalence of HIV infection, rising awareness of HIV treatment, and
the launch of innovative drugs. However, stringent regulatory policies for drug
approval and product recalls are expected to curb the growth of the global HIV
drug market during the assessment period. The global HIV drugs market is
currently dominated by several market players. The key players are involved in
product launches and strategic collaborations to strengthen their market
positions. Segmentation The global HIV drug market has been segmented based on type
and end-user. The market, based on type, has been divided into nucleoside
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5
antagonists, integrase inhibitors, post-attachment inhibitors, and
pharmacokinetic enhancers. The drugs in these different segments differ with
respect to their mechanism of treating the HIV infection. The different
approaches for treatment are, inhibiting HIV’s reverse transcriptase,
preventing HIV maturation, and preventing the entry of the virus into the host
cells, among others. The global HIV drugs market has been segmented based on
end-user, into hospitals & clinics, specialty centers, and others. The
hospitals & clinics segment is expected to hold the largest market share
due to an increasing number of hospitals. Key Players Some of the key players in the Global HIV Drugs Market
are Boehringer Ingelheim International, GmbH (Germany), Cipla Inc.
(India), Merck & Co., Inc. (US), AbbVie Inc. (US), Bristol-Myers Squibb
Company (US), Teva Pharmaceutical Industries Ltd (Israel), Gilead Sciences,
Inc. (US), F.Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Aurobindo
Pharma (India), Celltrion Healthcare Co., Ltd (South Korea), and ViiV
Healthcare (UK). Regional Analysis The market has been divided, by region, into Europe, the
Americas, Asia-Pacific, and the Middle East & Africa. The Americas holds
the largest market share. The HIV drugs market in the Americas has further been
branched into North America and Latin America, with the North American market
divided into the US and Canada. Europe is expected to be the second-largest
market owing to factors such as product launches by key players. The European
HIV drugs market has been categorized as Western Europe and Eastern Europe. The
Western European market has further been classified as Germany, France, the UK,
Italy, Spain, and the rest of Western Europe. The HIV drugs market in
Asia-Pacific has been segmented into Japan, China, India, South Korea,
Australia, and the rest of Asia-Pacific. Due to the growing awareness regarding
the use of HIV drugs and the increasing incidence of HIV in the region, the
market in Asia-Pacific is expected to be the fastest-growing. The HIV drugs
market in the Middle East & Africa has been divided into the Middle East
and Africa and is expected to hold the least market share. |